NCT07555574Recruiting
Defining Retinal Structures Using Hyperspectral Retinal Imaging
Source: ClinicalTrials.gov · Last updated 29 Apr 2026
Brief summary (registry, in English)
This study evaluates hyperspectral retinal imaging as a novel, non-invasive imaging technique to characterise retinal and optic nerve structures in healthy individuals and patients with eye disease. Hyperspectral imaging captures retinal data across multiple wavelengths to generate detailed spectral information that may reveal features not visible with conventional retinal photography. Approximately 1000 participants will undergo multi-modal ophthalmic imaging in Melbourne, Australia, including hyperspectral imaging, OCT, fundus photography, and related tests. The study aims to compare hyperspectral imaging with standard imaging methods and assess its ability to identify retinal biomarkers associated with diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 1000 (estimated)
- First submitted
- 8 Apr 2026
- Start date
- 1 Jan 2025
- Primary completion date
- 30 Dec 2028
- Lead sponsor
- Center for Eye Research Australia
- Diseases
- Glaucoma, Macular degeneration, Diabetic eye disease
- NCT number
- NCT07555574
What you commit to
- Study type: Interventional
- Planned participants: 1000
- From 1 Jan 2025 to the primary completion date, 30 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Ocular conditions preventing adequate retinal imaging (e.g., dense cataract, severe corneal opacity, vitreous haemorrhage)
- History of narrow anterior chamber angle or risk of angle closure glaucoma where dilation is considered unsafe
- Any condition that, in the investigator's opinion, would compromise participant safety or image quality
Other
- Inability to provide informed consent
- Known contraindication to pharmacological pupil dilation
Who the study is looking for
- Adults aged 18 years and older
- Able to provide informed consent
- Willing and able to attend a study visit at the Centre for Eye Research Australia
- Participants with diagnosed retinal or optic nerve disease (e.g., diabetic retinopathy, glaucoma, age-related macular degeneration)
- Age- and sex-matched healthy control participants without known retinal or optic nerve disease
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Centre for Eye Research Australia Coordinator of this site? Confirm its status | Melbourne | Australia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.